Robert Garnick stated emphatically, regarding the Bavituximab data from the phase2 second line NSCLC trial, that:
“...this is as compelling Phase II data as I've ever seen.”
Investors saw a trial that was powered only for phase2 move into stat sig territory, and double survival over the standard of care. Those are results that should turn heads in oncology. Obviously Dr. Garnick was impressed., which impresses me, considering his 17 new product approvals at Genentech over a 24 year period.
BusinessWeek EXECUTIVE PROFILE
Robert Garnick Ph.D.
Head of Regulatory Affairs, Peregrine Pharmaceuticals Inc.
“Senior Vice President of Regulatory, Quality & Compliance at Genentech Inc. since February 2001. During his 24-year career at Genentech, he was responsible for 17 new product approvals including most of the Genentech's top selling monoclonal antibody therapeutics such as Rituxan, Herceptin, Avastin and Lucentis.”
cj, Thanks for keeping investors up to speed on Peregrine.
IMO
sunstar
Market Data 
Markets 
AI
